VCCV: conservative transcriptomic corroboration for measurement prioritization of computational drug-target hypotheses.

VCCV enhances drug-target interaction predictions by conservatively integrating perturbational transcriptomics, improving discrimination and reducing ambiguity across five models.

• Why it matters: Accurate identification of the best drug-target candidates is crucial for effective therapeutics, but current models lack mechanisms to confirm cellular responses, risking false leads.
• What they did: VCCV employs a model-agnostic, covariance-based Bayesian update with an abstention option and follow-up gene panels, tested on five DTI models with improved ROC-AUC and likelihood metrics.
• The result: This approach provides a reliable, measurement-guided pathway from computational hypotheses to cellular validation, enabling more precise drug discovery and reducing false positives.